FDA awards fast track designation to Epion Therapeutics for its EpiSmart epithelium on cross linking system

13 October 2025 - Epion Therapeutics today announced that the US FDA granted fast track designation for EpiSmart Epithelium-On Cross-Linking System, ...

Read more →

Bicara Therapeutics announces ficerafusp alfa granted breakthrough therapy designation by US FDA for first-line HPV negative metastatic or with unresectable, recurrent head and neck squamous cell carcinoma

13 October 2025 - Bicara Therapeutics today announced that the US FDA has granted breakthrough therapy designation to ficerafusp alfa in ...

Read more →

BeOne Medicines’ sonrotoclax granted breakthrough therapy designation by US FDA

13 October 2025 - Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with ...

Read more →

Denali Therapeutics announces FDA review extension of BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome)

13 October 2025 - Denali Therapeutics today announced that the US FDA has extended its review timeline of the biologics license ...

Read more →

Blacksmith Medicines receives FDA qualified infectious disease product and fast track designation for FG-2101, a novel antibiotic targeting LpxC

13 October 2025 - Blacksmith Medicines announced today that the US FDA has granted qualified infectious disease product and the ...

Read more →

US FDA approves updated indication statement for Rinvoq (upadacitinib) for the treatment of inflammatory bowel disease

13 October 2025 - Updated indication allows the use of Rinvoq (upadacitinib) prior to the use of tumour necrosis factor blocking ...

Read more →

SQ Innovation announces FDA approval of Lasix ONYU for treatment of edema in heart failure

8 October 2025 -  -- SQ Innovation today announced that the US FDA has approved its drug-device combination Lasix ONYU ...

Read more →

FDA frants RMAT designation to Avobis Bio's implantable cell therapy AVB-114 for Crohn's perianal fistulas

3 October 2025 - Avobis Bio announced today that the US FDA has granted regenerative medicine advanced therapy designation for AVB-114, ...

Read more →

FDA approves expanded indication for Uzedy (risperidone) extended release injectable suspension as a treatment for adults living with bipolar I disorder

10 October 2025 - Teva Pharmaceuticals announced today that the US FDA has approved Uzedy (risperidone) as a once-monthly extended-release injectable ...

Read more →

Cidara Therapeutics receives US FDA breakthrough therapy designation for CD388 in seasonal influenza prevention

9 October 2025 - Cidara Therapeutics today announced that the US FDA has granted breakthrough therapy designation for CD388 for prevention ...

Read more →

Adcendo ApS announces FDA fast track designation granted to ADCE-D01 for the treatment of soft tissue sarcoma

9 October 2025 - Adcendo ApS today announced that the US FDA has granted fast track designation to ADCE-D01 for ...

Read more →

Celltrion receives US FDA approval for Eydenzelt (aflibercept-boav), biosimilar referencing Eylea (aflibercept)

9 October 2025 - Celltrion today announced that the US FDA has approved Eydenzelt (aflibercept-boav), biosimilar referencing Eylea (aflibercept), for the ...

Read more →

US FDA approves Boehringer’s Jascayd (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

9 October 2025 - Approval is based on results from two clinical trials, which showed reduction in forced vital capacity decline ...

Read more →

Richter and Hikma receive FDA approval for denosumab biosimilars Enoby and Xtrenbo, referencing Prolia and Xgeva

29 September 2025 - Gedeon Richter and Hikma Pharmaceuticals announce today that the US FDA has granted approval for the ...

Read more →

Xspray Pharma provides update on the FDA process for Dasynoc – observations at contract manufacturer delay approval

8 October 2025 - Xspray Pharma has received a complete response letter from the US FDA concerning the Company’s new ...

Read more →